Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02793583 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
A Phase 2 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 710
- Enrollment target
NCT02793583: Clinical Trial Phase 2 study, sponsored by TG Therapeutics.
NCT02793583 is a Phase 2 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 710 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (434% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02793583, a Phase 2 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 710 participants
- Enrollment target
Study Summary
Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Interventions
- BIOLOGICAL Ublituximab
- DRUG Umbralisib
- BIOLOGICAL Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2022-07-04 |
| Phase | Phase 2 |
Why NCT02793583 stopped before completion
NCT02793583 is an interventional study that assigns participants to a tested intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (434% higher).
The record links to 0 conditions, and to 3 interventions - of which Ublituximab is the first listed.
NCT02793583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02793583 about?
NCT02793583 is a clinical study titled "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma". Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
What is the current status of trial NCT02793583?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 710 participants. The study started on 2016-05-25. Estimated completion is 2022-07-04.
What interventions are being tested in trial NCT02793583?
The interventions under investigation include: Ublituximab (BIOLOGICAL), Umbralisib (DRUG), Bendamustine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02793583?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02793583's enrollment target sits among peer trials
710 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI